Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chronic myeloid leukemia

J M Goldman1

  • 1Department of Haematology, Royal Postgraduate Medical School, London, UK.

Current Opinion in Hematology
|July 1, 1997
PubMed
Summary
This summary is machine-generated.

Understanding the BCR-ABL gene and its oncogenic mechanisms is crucial for leukemia treatment. Current therapies like interferon alfa and allografting offer benefits but face management challenges, with autografting showing promise.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Overexpression of EVI-1 in blast crisis of chronic myeloid leukemia.

Leukemia·1996
Same author

Organ-specific contribution to circulating C7 levels by the bone marrow and liver in humans.

European journal of immunology·1996
Same author

Phenotype and progeny of primitive adherent human hematopoietic progenitors.

Leukemia·1996
Same author

Expression of the LH2 gene in chronic myeloid leukaemia cells.

Leukemia·1996
Same author

Reverse transcription/polymerase chain reaction (RT/PCR) amplification of very small numbers of transcripts: the risk in misinterpreting negative results.

Leukemia·1996
Same author

Rarity of microsatellite alterations in acute myeloid leukaemia.

British journal of cancer·1996
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The molecular basis of the BCR-ABL chimeric gene, including the newly identified mu-bcr region, is increasingly understood.
  • The oncogenic mechanism of p210BCR-ABL, despite its interactions with various proteins, remains incompletely elucidated.
  • Treatment decisions for younger patients with BCR-ABL-positive malignancies are complex, balancing efficacy and toxicity.

Purpose of the Study:

  • To review current knowledge on the BCR-ABL gene and its oncogenic potential.
  • To discuss the complexities and controversies surrounding treatment options for younger patients.
  • To propose a management algorithm for patients not in clinical trials.

Main Methods:

  • Literature review and synthesis of existing research on BCR-ABL gene.

Related Experiment Videos

  • Analysis of treatment outcomes for interferon alfa, allografting, and autografting.
  • Development of a proposed clinical management algorithm.

    • Main Results:

    • Interferon alfa extends survival compared to cytotoxic drugs, but optimal use is debated.
    • Allografting is a primary option for patients with matched siblings; its role for others is uncertain.
    • Donor lymphocyte infusions can reinduce remission post-allografting, with the graft-versus-leukemia effect mechanism unclear.
    • Autografting using Philadelphia-chromosome-negative progenitor cells shows potential.

    Conclusions:

    • Further research is needed to clarify the oncogenic mechanisms of p210BCR-ABL.
    • Standardization of treatment protocols, including dosage and response definitions for interferon alfa, is required.
    • The role of allografting and the graft-versus-leukemia effect warrant further investigation.
    • A dynamic management algorithm is proposed to guide clinical decisions for patients outside of prospective studies.